Zhejiang Teruisi gets rights to EpimAb's bispecific antibody

EpimAb Biotherapeutics Inc. (Shanghai, China) granted Zhejiang Teruisi

Read the full 86 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE